Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure

Overview

Journal ACS Med Chem Lett

Publisher American Chemical Society

Specialty Chemistry

Date 2017 Nov 21

PMID 29152047

Citations 3

Authors

Mahesh S Deshmukh

Nidhi Jain

Affiliations

Soon will be listed here.

Abstract

A series of novel oxazolidinone antibacterials with diverse fused heteroaryl C-rings bearing hydrogen bond donor and hydrogen bond acceptor functionalities were designed and synthesized. The compound with benzoxazinone C-ring substructure () exhibited superior activity compared to linezolid against a panel of Gram-positive and Gram-negative bacteria. Structural modifications at C5-side chain of resulted in identification of several potent compounds (, , , and ). Selected compounds and showed very good microsomal stability and no CYP liability, thus clearing preliminary safety hurdles. A docking model of binding to 23S rRNA suggested that the increased potency of is due to additional ligand-receptor interaction.

Citing Articles

Oxazolidinones as versatile scaffolds in medicinal chemistry.

Fernandes G, Scarim C, Kim S, Wu J, Castagnolo D RSC Med Chem. 2023; 14(5):823-847.

PMID: 37252095 PMC: 10211318. DOI: 10.1039/d2md00415a.

Structure-Uptake Relationship Studies of Oxazolidinones in Gram-Negative ESKAPE Pathogens.

Hu Z, Leus I, Chandar B, Sherborne B, Avila Q, Rybenkov V J Med Chem. 2022; 65(20):14144-14179.

PMID: 36257060 PMC: 9942527. DOI: 10.1021/acs.jmedchem.2c01349.

Synthesis and Biological Evaluation of 3-(Pyridine-3-yl)-2-Oxazolidinone Derivatives as Antibacterial Agents.

Jin B, Wang T, Chen J, Liu X, Zhang Y, Zhang X Front Chem. 2022; 10:949813.

PMID: 35923260 PMC: 9339906. DOI: 10.3389/fchem.2022.949813.

References

Xin Q, Fan H, Guo B, He H, Gao S, Wang H . Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents. J Med Chem. 2011; 54(21):7493-502. DOI: 10.1021/jm200614t. View

Shaw K, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar C . In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008; 52(12):4442-7. PMC: 2592863. DOI: 10.1128/AAC.00859-08. View

Michalska K, Karpiuk I, Krol M, Tyski S . Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg Med Chem. 2013; 21(3):577-91. DOI: 10.1016/j.bmc.2012.11.036. View

Renslo A . Antibacterial oxazolidinones: emerging structure-toxicity relationships. Expert Rev Anti Infect Ther. 2010; 8(5):565-74. DOI: 10.1586/eri.10.26. View

Gordeev M, Yuan Z . New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014; 57(11):4487-97. DOI: 10.1021/jm401931e. View

Pucci M, Bush K . Investigational antimicrobial agents of 2013. Clin Microbiol Rev. 2013; 26(4):792-821. PMC: 3811234. DOI: 10.1128/CMR.00033-13. View

Ager S, Gould K . Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist. 2012; 5:87-102. PMC: 3392139. DOI: 10.2147/IDR.S25890. View

Seetharamsingh B, Ramesh R, Dange S, Khairnar P, Singhal S, Upadhyay D . Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure. ACS Med Chem Lett. 2015; 6(11):1105-10. PMC: 4645245. DOI: 10.1021/acsmedchemlett.5b00213. View

Paulen A, Gasser V, Hoegy F, Perraud Q, Pesset B, Schalk I . Synthesis and antibiotic activity of oxazolidinone-catechol conjugates against Pseudomonas aeruginosa. Org Biomol Chem. 2015; 13(47):11567-79. DOI: 10.1039/c5ob01859e. View

10.

Suzuki H, Utsunomiya I, Shudo K, Fukuhara N, Iwaki T, Yasukata T . Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit. Eur J Med Chem. 2013; 63:811-25. DOI: 10.1016/j.ejmech.2013.03.003. View

11.

Im W, Choi S, Park J, Choi S, Finn J, Yoon S . Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem. 2011; 46(4):1027-39. DOI: 10.1016/j.ejmech.2011.01.014. View

12.

Gold H . Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis. 2001; 33(2):210-9. DOI: 10.1086/321815. View

13.

Suzuki H, Utsunomiya I, Shudo K, Fujimura T, Tsuji M, Kato I . Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure. ACS Med Chem Lett. 2014; 4(11):1074-8. PMC: 4027242. DOI: 10.1021/ml400280z. View

14.

Khera M, Cliffe I, Mathur T, Prakash O . Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents. Bioorg Med Chem Lett. 2011; 21(10):2887-9. DOI: 10.1016/j.bmcl.2011.03.075. View

15.

Yang T, Chen G, Sang Z, Liu Y, Yang X, Chang Y . Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies. J Med Chem. 2015; 58(16):6389-409. DOI: 10.1021/acs.jmedchem.5b00152. View

16.

Renslo A, Luehr G, Gordeev M . Recent developments in the identification of novel oxazolidinone antibacterial agents. Bioorg Med Chem. 2006; 14(12):4227-40. DOI: 10.1016/j.bmc.2006.01.068. View

17.

Song J, Jung S, Ko K, Kim N, Son J, Chang H . High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother. 2004; 48(6):2101-7. PMC: 415617. DOI: 10.1128/AAC.48.6.2101-2107.2004. View

18.

Hutchinson D . Oxazolidinone antibacterial agents: a critical review. Curr Top Med Chem. 2003; 3(9):1021-42. DOI: 10.2174/1568026033452195. View

19.

. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010; 50(8):1081-3. DOI: 10.1086/652237. View

20.

Paget S, Foleno B, Boggs C, Goldschmidt R, Hlasta D, Weidner-Wells M . Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones. Bioorg Med Chem Lett. 2003; 13(23):4173-7. DOI: 10.1016/j.bmcl.2003.08.031. View